LOTIS-5 trial: ADC Therapeutics (NYSE: ADCT) shows PFS gain but higher toxicity
Rhea-AI Filing Summary
ADC Therapeutics reported topline Phase 3 LOTIS-5 results for ZYNLONTA plus rituximab in relapsed or refractory diffuse large B‑cell lymphoma. The study met its primary endpoint: progression‑free survival improved to a median 6.1 months versus 4.7 months with R‑GemOx (hazard ratio 0.73; p=0.008).
Overall response rate was higher at 58.1% versus 45.2%, with complete responses of 39.5% versus 26.7%. Median duration of response was 9.2 versus 7.7 months and complete responses lasted 16.8 versus 12.3 months, with 48.5% versus 16.7% of complete responders still in remission at 24 months.
Overall survival showed no detrimental effect (hazard ratio 0.96). Safety was mixed: overall treatment‑emergent adverse event rates were similar, but serious events, withdrawals, and Grade 5 events were higher with ZYNLONTA plus rituximab (Grade 5 in 13.2% versus 4.6%, mostly in patients aged 75 or older). The company plans a pre‑sBLA FDA meeting in August and a supplemental BLA submission in the fourth quarter of 2026.
Positive
- LOTIS-5 met its primary endpoint with ZYNLONTA plus rituximab significantly improving progression-free survival versus R‑GemOx (hazard ratio 0.73; median 6.1 vs 4.7 months; p=0.008).
- Deep and durable responses were observed, with complete response rate 39.5% vs 26.7% and median duration of complete response 16.8 vs 12.3 months; 48.5% vs 16.7% of complete responders remained in remission at 24 months.
- Regulatory path is defined, with a pre‑sBLA FDA meeting planned in August and a supplemental BLA submission targeted for the fourth quarter of 2026 based on LOTIS-5 topline results.
Negative
- Higher serious toxicity was seen with ZYNLONTA plus rituximab, including serious adverse events in 49.0% vs 34.5% of patients and treatment-emergent Grade 5 events in 13.2% vs 4.6%, mainly in patients aged 75 years or older.
- More treatment discontinuations occurred in the ZYNLONTA plus rituximab arm, with 25.5% of patients stopping study drug due to adverse events versus 9.1% with R‑GemOx, which may limit use in frailer populations.
- Overall survival benefit was not demonstrated at this stage, with a hazard ratio of 0.96, so the efficacy advantage is currently confined to progression-free survival and response metrics.
Insights
LOTIS-5 shows stronger disease control but with higher serious toxicity, setting up a pivotal FDA discussion.
ADC Therapeutics delivered a positive Phase 3 readout: ZYNLONTA plus rituximab significantly improved progression-free survival versus R‑GemOx (hazard ratio 0.73) and raised complete response rates to 39.5% versus 26.7%. Durability is notable, with median duration of complete response at 16.8 versus 12.3 months and nearly half of complete responders still in remission at 24 months.
Overall survival showed no detrimental effect (hazard ratio 0.96) despite earlier and more frequent switches to new anti‑lymphoma therapies in the control arm. This pattern helps explain why the disease-control benefits did not yet translate into a clear survival separation in the topline data.
Safety is the main counterweight. While overall Grade ≥3 event rates were comparable, ZYNLONTA plus rituximab had higher serious adverse events (49.0% vs 34.5%), more treatment-related withdrawals (25.5% vs 9.1%), and more Grade 5 events (13.2% vs 4.6%), concentrated in patients aged ≥75%. The planned pre‑sBLA meeting in August 2026 and targeted sBLA filing in Q4 2026 will clarify how regulators view this benefit‑risk profile, particularly for older and more fragile patients.
8-K Event Classification
Key Figures
Key Terms
progression-free survival medical
overall response rate medical
treatment emergent adverse event medical
supplemental Biologics License Application regulatory
hazard ratio medical
accelerated approval regulatory
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date
of Earliest Event Reported):
(Exact Name of Registrant as Specified in Its Charter)
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
N/A (IRS Employer Identification Number) |
|
(Address of Principal Executive Offices) (Zip Code) |
+ (Registrant’s Telephone Number) |
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 C.F.R. §230.405) or Rule 12b-2 of the Securities Exchange Act of
1934 (17 C.F.R. §240.12b-2). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
In connection with the events described under Item 8.01 below, ADC Therapeutics SA (the “Company”) issued a press release and made available a presentation, copies of which are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated by reference herein.
The information contained in this Item 7.01 and the associated exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
On June 3, 2026, the Company announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (“r/r DLBCL”). The LOTIS-5 trial is a randomized, open-label, two-arm, multicenter study evaluating ZYNLONTA plus rituximab versus the standard immunochemotherapy rituximab gemcitabine-oxaliplatin (R-GemOx), for the treatment of r/r DLBCL after one or more lines of systemic therapy.
The study met the primary endpoint of progression-free survival (“PFS”) (per independent review committee) with statistical significance (HR = 0.73; p-value = 0.008 two sided), with a median PFS of 6.1 months for ZYNLONTA plus rituximab vs 4.7 months for R-GemOx. Overall survival showed no detrimental effect with ZYNLONTA plus rituximab compared to the control arm (HR = 0.96, impacted by the earlier use and a higher rate of new anti-lymphoma treatment switching in the control arm). Overall response rate (“ORR”) was 58.1% vs. 45.2%, complete response (“CR”) rate was 39.5% vs. 26.7%, median duration of response (“DOR”) was 9.2 months vs. 7.7 months, and median duration of CRs (“DoCR”) was 16.8 months vs. 12.3 months for ZYNLONTA plus rituximab compared to R-GemOx, respectively. Of patients achieving CR, 48.5% vs. 16.7% remained in CR at 24 months in favor of ZYNLONTA plus rituximab. Of note, results in North America were consistent with the overall study results.
Overall, treatment emergent adverse event (“TEAE”) rates were similar between arms (98.5% vs. 97.5%). Higher rates of serious adverse events (“SAEs”) were seen in the test arm (49.0% vs. 34.5%). Grade ≥3 TEAEs observed in > 5% of patients were hematologic (40.7% vs. 59.4%), followed by infection/infestations (24.5% vs. 15.7%), then hepatotoxicity (17.2% vs. 8.1%) and oedema/effusion (7.4% vs. 0.5%) when comparing ZYNLONTA plus rituximab to R-GemOx. A higher rate of Grade 5 TEAEs was observed in the ZYNLONTA plus rituximab arm (27 pts/13.2%) vs. R-GemOx (9 pts/4.6%). Of note, the majority of Grade 5 TEAEs in the test arm occurred in patients aged 75 years or older. Higher rates of TEAEs leading to any drug withdrawal occurred in the ZYNLONTA plus rituximab arm (25.5% vs. 9.1%). In this study, the TEAE reporting window was defined as 105 days after the last dose of study treatment or the start of new anticancer therapy, whichever is earlier. The rates of TEAEs in this study were impacted by the longer overall TEAE observation time in the test vs. control arm. This difference is primarily driven by a higher rate of and earlier switching to subsequent therapies in the control arm.
Based on these topline results from LOTIS-5, the Company plans to conduct a pre-Supplemental Biologics License Application (“sBLA”) meeting with the U.S. Food and Drug Administration (“FDA”) in August and is preparing for a planned sBLA submission in the fourth quarter of 2026. In addition, the Company will continue to evaluate a broad range of value maximizing alternatives, including but not limited to near-term cost reduction initiatives.
This report contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the adequacy of the LOTIS-5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA; the timing, submission and acceptance of an sBLA submission related to LOTIS-5 and potential approval; the actual and perceived benefit-risk profile for ZYNLONTA as studied in the LOTIS-5 trial; the assessment of the data from LOTIS-5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub-populations; the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions; our ability to identify and execute value-maximizing options and the cost and impact of such options; our expected cash runway into at least 2028; our ability to comply with the terms of our indebtedness; changes in our regulatory and commercial strategy; the Company's ability to sustain or grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing, results and publication of the Company's clinical trials including LOTIS-7; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description |
| 99.1 | Press release dated June 3, 2026 |
| 99.2 | Presentation dated June 3, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ADC Therapeutics SA | ||
| Date: June 3, 2026 | ||
| By: | /s/ Peter J. Graham | |
| Name: | Peter J. Graham | |
| Title: | Chief Legal Officer | |
Exhibit 99.1
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Company to host conference call today at 4:30 p.m. EDT
LAUSANNE, Switzerland, June 3, 2026 – ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA plus rituximab achieved statistical significance on the trial’s primary endpoint of progression-free survival (PFS) and demonstrated no detrimental effect on the key secondary efficacy endpoint of overall survival (OS). In addition, a higher complete response (CR) rate and duration of CRs (DoCR) were observed with ZYNLONTA plus rituximab. Overall, treatment emergent adverse event (TEAE) rates were similar between arms. Similar rates of overall Grade ≥3 TEAEs greater than 5% were observed across both arms, with hematologic TEAEs higher in the control arm and infection, hepatotoxicity, and edema/effusion higher in the test arm. Serious adverse events (SAEs), TEAEs leading to study drug withdrawal, and Grade 5 events were higher in the test arm, with the majority of Grade 5 TEAEs in the test arm occurring in patients aged 75 years or older.
“In the context of a positive study, based on the totality of the data, we plan to discuss the benefit-risk profile of this combination with the U.S. FDA as we prepare for the planned supplemental Biologics License Application (sBLA) filing,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “We would like to extend our thanks to the patients, investigators, and clinical teams who contributed to this important trial.”
The LOTIS-5 trial is a randomized, open-label, two-arm, multicenter study evaluating ZYNLONTA plus rituximab versus the standard immunochemotherapy rituximab gemcitabine-oxaliplatin (R-GemOx), for the treatment of r/r DLBCL after one or more lines of systemic therapy. The study met the primary endpoint of PFS (per independent review committee) with statistical significance (HR = 0.73; p-value = 0.008 two sided), with a median PFS of 6.1 months for ZYNLONTA plus rituximab vs 4.7 months for R-GemOx. Overall survival showed no detrimental effect with ZYNLONTA plus rituximab compared to the control arm (HR = 0.96, impacted by the earlier use and a higher rate of new anti-lymphoma treatment switching in the control arm). Overall response rate (ORR) was 58.1% vs. 45.2%, CR rate was 39.5% vs. 26.7%, median duration of response (DOR) was 9.2 months vs. 7.7 months, and median DoCR was 16.8 months vs. 12.3 months for ZYNLONTA plus rituximab compared to R-GemOx, respectively. Of patients achieving CR, 48.5% vs. 16.7% remained in CR at 24 months in favor of ZYNLONTA plus rituximab. Of note, results in North America were consistent with the overall study results.
Overall, TEAE rates were similar between arms (98.5% vs. 97.5%). Higher rates of SAEs were seen in the test arm (49.0% vs. 34.5%). Grade ≥3 TEAEs observed in > 5% of patients were hematologic (40.7% vs. 59.4%), followed by infection/infestations (24.5% vs. 15.7%), then hepatotoxicity (17.2% vs. 8.1%) and oedema/effusion (7.4% vs. 0.5%) when comparing ZYNLONTA plus rituximab to R-GemOx. A higher rate of Grade 5 TEAEs was observed in the ZYNLONTA plus rituximab arm (27 pts/13.2%) vs. R-GemOx (9 pts/4.6%). Of note, the majority of Grade 5 TEAEs in the test arm occurred in patients aged 75 years or older. Higher rates of TEAEs leading to any drug withdrawal occurred in the ZYNLONTA plus rituximab arm (25.5% vs. 9.1%). In this study, the TEAE reporting window was defined as 105 days after the last dose of study treatment or the start of new anticancer therapy, whichever is earlier. The rates of TEAEs in this study were impacted by the longer overall TEAE observation time in the test vs. control arm. This difference is primarily driven by a higher rate of and earlier switching to subsequent therapies in the control arm.
“LOTIS-5 was designed to address a clear unmet need in r/r DLBCL in patients who cannot access or who progress on a CAR-T or other complex therapies,” said Mehdi Hamadani, MD, Professor of Medicine, Associate Director of Clinical Research, Section Chief of Hematologic Malignancies at Medical College of Wisconsin and principal investigator for the trial. “Based on these results, I believe this combination may provide an additional option in treating relapsed or refractory DLBCL.”
“Based on these topline results from LOTIS-5, we look forward to discussing next steps for this combination of ZYNLONTA plus rituximab with the U.S. FDA,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. “We intend to conduct a pre-sBLA meeting in August and are preparing for a planned sBLA submission in the fourth quarter of 2026.”
In addition, the Company will continue to evaluate a broad range of value maximizing alternatives, including but not limited to near-term cost reduction initiatives.
For more information about LOTIS-5, please visit https://clinicaltrials.gov/ (identifier: NCT04384484).
Conference Call Details
ADC Therapeutics management will host a conference call and live audio webcast to discuss the LOTIS-5 results today at 4:30 p.m. EDT. To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events & Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.
About ZYNLONTA®
ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at www.ZYNLONTA.com.
ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).
ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.
Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the adequacy of the LOTIS-5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA; the timing, submission and acceptance of an sBLA submission related to LOTIS-5 and potential approval; the actual and perceived benefit-risk profile for ZYNLONTA as studied in the LOTIS-5 trial; the assessment of the data from LOTIS-5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub-populations; the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions; our ability to identify and execute value-maximizing options and the cost and impact of such options; our expected cash runway into at least 2028; our ability to comply with the terms of our indebtedness; changes in our regulatory and commercial strategy; the Company's ability to sustain or grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing, results and publication of the Company's clinical trials including LOTIS-7; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.
CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
Exhibit 99.2
LOTIS - 5 Topline Results Presentation JUNE 3, 2026
Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by th e presenter or ADC Therapeutics or any officer, director, employee, agent or advisor of ADC Therapeutics. This presentation does not purport to be all - inclusive or to contain all of the information you may desire. Information provided in this presentation and any accompanying oral presentation speak only as of the date hereof. This presentation contains forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward - looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believ e", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward - looking statements contain these identi fying words. Forward - looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such difference s i nclude, but are not limited to: the adequacy of the LOTIS - 5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign ju ris dictions for our product; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA; the timing, submission and accept anc e of an sBLA submission related to LOTIS - 5 and potential approval; the actual and perceived benefit - risk profile for ZYNLONTA as studied in the LOTIS - 5 trial; the assessment of the data from LOTI S - 5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub - populations; the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions; our ability to identify and execute value - maximizing options and the cost and impact of such options; our expected cash runway into at least 20 28; our ability to comply with the terms of our indebtedness; changes in our regulatory and commercial strategy; the Company's ability to sustain or grow ZYNLONTA® revenue in the United States and p ote ntial peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their abi lit y to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing, results and publication of the Company's clinical trials including LOTIS - 7; the timing, publication and results of investigator - initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions f or the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Mana gem ent and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and rep ay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and com mercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on o ur business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in t he forward - looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10 - K and in the Company's other periodic and current reports and filings with the U.S. Secur ities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be ma ter ially different from any future results, performance, achievements or prospects expressed in or implied by such forward - looking statements. The Company cautions investors not to place undue reliance on the forward - looking statements contained in this document. Forward - looking statements are based on our management’s beliefs and assumptions and on information currently available to our m anagement. No assurance can be given that such future results will be achieved. Such forward - looking statements contained in this presentation speak only as of the date of this presentation. The Company expressly disclaim any obligation or undertaking to update these forward - looking statements contained in this presentation to reflect any change in our expectations or any change in event s, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accura cy of any such forward - looking statements. Certain information contained in this presentation relates to or is based on studies, publications, surveys, and other data d eri ved from third - party sources and our own internal estimates and research. While we believe these third - party sources to be reliable as of the date of this presentation, we have not independently verifie d, and we make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third - party sources. In addition, all of the market data included in this present ation involve a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, although we believe our own internal research is re liable, such research has not been verified by any independent source. LOTIS - 5 Topline Results 2
LOTIS - 5 Topline Results 3 Agenda Introduction Ameet Mallik Chief Executive Officer 01 Clinical Highlights Mohamed Zaki Chief Medical Officer 02 03 Q&A 04 Next Steps Ameet Mallik Chief Executive Officer
LOTIS - 5 Topline Results 4 ZYNLONTA ® is an approved, highly - potent, single - agent anti - CD19 ADC in r/r DLBCL ZYNLONTA ( loncastuximab tesirine ) is a CD19 - directed ADC indicated as monotherapy for the treatment of adult patients with relapsed or refractory large B - cell lymphoma after two or more lines of systemic therapy; currently FDA approved under accelerated approval Please visit ZYNLONTA.com for complete prescribing information including indication, warnings and precautions. ADC = antibody drug conjugate; PBD = Pyrrolobenzodiazepine ; DNA = deoxyribonucleic acid; FDA = Food and Drug Administration; r/r = relapsed / refractory; DLBCL = diffuse large b - cell lymphoma Protease - cleavable valine - alanine linker PBD dimer - cytotoxic alkylating agent CD19 directed mAb Binding to CD19 on cell - surface Endocytosis of ADC - antigen complex Lysosomal degradation Release of PBD payload Binding of cytotoxic PBD payload to DNA DNA damage induced apoptosis PBD payload DNA CD19 protein Malignant B Cell ZYNLONTA ANTI - CD19 ADC Accessible across care settings Manageable safety profile ~5K patients treated since 2021 FDA approval Rapid, deep, durable efficacy in 3L+ DLBCL
LOTIS - 5 Topline Results 5 Advancing ZYNLONTA Development Into 2L+ B - Cell Lymphomas DLBCL = diffuse large b - cell lymphoma; FL = follicular lymphoma; MZL = marginal zone lymphoma, IIT = Investigator initiated tria l → 2L+ treatment choice is based largely on achieving a rapid and durable complete response , within the accessible treatment options for each individual patient → ZYNLONTA is being studied in combination with two different approved agents ZYNLONTA + rituximab Ph 3 LOTIS - 5 ZYNLONTA + glofitamab Ph 1b LOTIS - 7 2L+ DLBCL → 2L+ treatment choice is driven by tolerability and QoL as well as rate and durability of overall response for both MZL and FL → ZYNLONTA is being studied in combination and as monotherapy r/r MZL and FL, respectively ZYNLONTA + rituximab Ph 2 FL IIT ZYNLONTA Ph 2 MZL IIT 2L+ Indolent Lymphomas Q4 26 Q4 26 Q2 27 Data Readout
LOTIS - 5 Topline Results 6 ZYNLONTA has the Potential to Play a Role in Two Distinct r/r DLBCL Segments Through a Complementary Approach + Based on internal market research conducted July to August 2024 (n=160 US Hem/ Oncs ), glofitamab ODAC briefing book dated May 20, 2025, and Komodo claims data January - June 2025; *2026 Clarivate Non - Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Disease Landscape and Forecast r/r = relapsed refractory; DLBCL = diffuse large b - cell lymphoma; SCT = stem cell transplant 10% 20% 30% 5% 10% 20% 5% 2L ~12k patients 3L+ ~6k patients Complex Therapies Broadly Accessible Therapies Bispecifics CAR - T SCT Pola+BR Tafa+Len R - Chemo other 10% 5% 10% 5% 10% 35% 20% 5% Complex Therapies Broadly Accessible Therapies ~10% ZYNLONTA Current r/r DLBCL U.S. Market + 2L+ DLBCL market, comprised of two key segments, projected to be ~$3Bn in U.S. by 2030* □ Broadly accessible outpatient therapies which can be administered across care settings □ Complex therapies with unique patient management and infrastructure requirements ZYNLONTA + rituximab LOTIS - 5 ZYNLONTA + glofitamab LOTIS - 7
LOTIS - 5 Topline Results 7 LOTIS - 5: Phase 3 Confirmatory Trial of ZYNLONTA in Combination with Rituximab in 2L+ DLBCL Lonca 150 µg/kg + rituximab 375 mg/m2 Q3W for 2 cycles, then Lonca 75 µg/kg + rituximab 375 mg/m2 Q3W for up to 6 additional cycles Part 1 safety run - in (N=20) previously published DLBCL = diffuse large B - cell lymphoma; SCT = stem cell transplant; Q3W = every three weeks, Q2W = every two weeks; PFS = progres sion free survival; OS = overall survival; ORR = overall response rate; CRR = complete response rate; DOR = duration of response; DoCR = duration of complete response; PK = pharmacokinetic; PRO = patient reported outcomes; EOT = end of treatment Data cut off: February 16, 2026. **after EOT until withdrawal of consent, loss to follow - up, or death — whichever occurs first Key Inclusion/Exclusion Criteria → Adults with a pathologic diagnosis of 2L+ DLBCL who are not a candidate for SCT based on investigator assessment Endpoints → Primary endpoint: PFS by independent central review; → Key secondary endpoint: OS → Other secondary endpoints: ORR/CRR, DOR, DoCR , safety, PK parameters, immunogenicity, and PROs Cycles 1 – 2 Cycles 3 – (up to) 8 Follow Up for PFS and OS for up to 4 years** Loncastuximab 150 µg/kg + rituximab 375 mg/m 2 Q3W Loncastuximab 75 µg/kg + rituximab 375 mg/m 2 Q3W R - GemOx : rituximab 375 mg/m 2 + gemcitabine 1000 mg/m 2 + oxaliplatin 100 mg/m 2 Q2W Clinical Trial Design Randomized 1:1 (N=420) 210 patients per arm
LOTIS - 5 Topline Results 8 Patient population enrolled generally balanced between arms Baseline Patient Characteristics Percentages may not add due to rounding. Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin; ECOG = Eastern Cooperative Oncology Group; ROW = rest of world; DLBCL = diffuse large B - cell lymphoma; NOS = not otherwise specified; HGBCL = high grade B - cell lymphoma; DH = double hi t; TH = triple hit; GCB = germinal center B - cell; ABC = Activated B - cell Like; IPI = international prognostic index ITT Population (N=420); Data cut off: February 16, 2026. R - GemOx N=210 (%) Lonca - R N=210 (%) Characteristic DLBCL Subtype 98 (46.7%) 107 (51.0%) 5 (2.4%) 98 (46.7%) 94 (44.8%) 18 (8.6%) GCB Non - GCB (including ABC) Unknown 12 (5.7%) 15 (7.1%) Double/Triple hit 137 (65.2%) 132 (62.9%) IPI Score 3 - 5 28 (13.3%) 29 (13.8%) Bulky Disease (≥10 cm) Number of prior lines of therapy 133 (63.3%) 77 (36.7%) 133 (63.3%) 77 (36.7%) 1 ≥2 1 (1,6) 1 (0,5) Median (range) 12 (5.7%) 3 (1.4%) Prior Stem Cell Transplant 5 (2.4%) 5 (2.4%) Prior CAR - T Therapy 128 (61.0%) 131 (62.4%) Refractory to primary therapy * 88 (41.9%) 88 (41.9%) Refractory to last prior therapy ** R - GemOx N=210 (%) Lonca - R N=210 (%) Characteristic 72 [27,91] 79 (37.6%) 73 [34,91] 87 (41.4%) Median age yr [range] ≥75 years 113 (53.8%) 99 (47.1%) Male ECOG Perf Status 73 (34.8%) 93 (44.3%) 43 (20.5%) 1 (0.5%) 63 (30.0%) 121 (57.6%) 26 (12.4%) 0 0 1 2 ≥3 Regional Enrollment 71 (33.8%) 45 (21.4%) 17 (8.1%) 77 (36.7%) 91 (43.3%) 46 (21.9%) 13 (6.2%) 60 (28.6%) Europe, n (%) Asia, n (%) North America, n (%) ROW, n (%) Large B - Cell Lymphoma Histology 191 (91.0%) 10 (4.8%) 9 (4.3%) 183 (87.1%) 15 (7.1%) 12 (5.7%) DLBCL NOS HGBCL with DH/TH HGBCL NOS * Failed to respond, or disease recurred within 6 months after first line treatment ended ** Failed to respond, or disease recurrence following the most recent line of treatment ended
LOTIS - 5 Topline Results 9 Summary of key results LOTIS - 5: Efficacy PFS = progression free survival; HR = hazard ratio; OS = overall survival; NALT = new anti - lymphoma therapy; CR = complete respo nse; Data cut off: February 16, 2026. Study met primary PFS endpoint with statistical significance (HR=0.73, two - sided p - value 0.008) No detrimental effect on key secondary efficacy endpoint of OS (HR=0.96, impacted by earlier use and higher rate of NALT in control arm) Higher CR rate in ZYNLONTA plus rituximab arm (~40% vs. ~27%) Longer duration of CRs with higher proportion maintained at 24 - months (~49% vs. ~17%) in ZYNLONTA plus rituximab arm Results in North America region consistent with overall study results
LOTIS - 5 Topline Results 10 Met primary endpoint of PFS with statistical significance Progression Free Survival by IRC *Other reasons include starting NALT without confirmed PD, no postbaseline assessment, or consent withdrawal. IRC = Independent Review Committee, PFS = progression free survival; Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin; PD = progressive disease; NALT = new anti - lymphoma therapy ITT Population (N=420); Data cut off: February 16, 2026. # of Event/Censored Event/Censored Description Total 420 R - GemOx N=210 Lonca - R N=210 279 (66.4%) 141 (67.1%) 138 (65.7%) Total # of Events 118 93 Disease Progression 23 45 Death 141 (33.6%) 69 (32.9%) 72 (34.3%) Total Censored 52 (12.4%) 16 (7.6%) 36 (17.1%) Ongoing 89 (21.2%) 53 (25.2%) 36 (17.1%) Censored due to other reasons* R - GemOx, % Lonca - R, % Event - free rate (95% CI) 38.9 (31.4, 46.3) 50.4 (43.0, 57.3) 6M 23.7 (17.2, 30.8) 29.6 (22.9, 36.5) 12M 14.7 (9.2, 21.5) 25.1 (18.7, 32.0) 18M 9.5 (4.8, 16.2) 23.2 (16.9, 30.1) 24M ͏ ϟ ͏ ͏ ϟ ͐ ͏ ϟ ͑ ͏ ϟ ͒ ͏ ϟ ͓ ͏ ϟ ͔ ͏ ϟ ͕ ͏ ϟ ͖ ͏ ϟ ͗ ͏ ϟ ͘ ͐ ϟ ͏ ͏ ϟ ͏ ͏ ϟ ͐ ͏ ϟ ͑ ͏ ϟ ͒ ͏ ϟ ͓ ͏ ϟ ͔ ͏ ϟ ͕ ͏ ϟ ͖ ͏ ϟ ͗ ͏ ϟ ͘ ͐ ϟ ͏ ť ϙ Ř Ė Ŝ ħ ϙϡ “ Ė ı ô ϙ ϼ ı ĺ IJ ť ē Ŝ Ͻ ͑ ͐͏ ͑ ͐͏ ͐ ͗͐ ͐ ͗͐ ͐ ͐͑ ͐ ͐͑ ͗ ͘ ͗ ͘ ͗ ͏ ͗ ͏ ͖ ͐ ͖ ͐ ͔ ͕ ͔ ͕ ͔ ͏ ͔ ͏ ͓ ͒ ͓ ͒ ͓ ͐ ͓ ͐ ͒ ͕ ͒ ͕ ͒ ͓ ͒ ͓ ͒ ͏ ͒ ͏ ͑ ͕ ͑ ͕ ͑ ͔ ͑ ͔ ͑ ͑ ͑ ͑ ͐ ͘ ͐ ͘ ͐ ͓ ͐ ͓ ͐ ͑ ͐ ͑ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͏ ͐ ͏ ͘ ͘ ͓ ͓ ͑ ͑ ͑ ͑ ͑ ͑ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͐ ͐ ͑ ͑ ͒ ͒ ͓ ͓ ͔ ͔ ͕ ͕ ͖ ͖ ͗ ͗ ͘ ͘ ͐ ͏ ͐ ͏ ͐ ͐ ͐ ͐ ͐ ͑ ͐ ͑ ͐ ͒ ͐ ͒ ͐ ͓ ͐ ͓ ͐ ͔ ͐ ͔ ͐ ͕ ͐ ͕ ͐ ͖ ͐ ͖ ͐ ͗ ͐ ͗ ͐ ͘ ͐ ͘ ͑ ͏ ͑ ͏ ͑ ͐ ͑ ͐ ͑ ͑ ͑ ͑ ͑ ͒ ͑ ͒ ͑ ͓ ͑ ͓ ͑ ͔ ͑ ͔ ͑ ͕ ͑ ͕ ͑ ͖ ͑ ͖ ͑ ͗ ͑ ͗ ͑ ͘ ͑ ͘ ͒ ͏ ͒ ͏ ͒ ͐ ͒ ͐ ͒ ͑ ͒ ͑ ͒ ͒ ͒ ͒ ͒ ͓ ͒ ͓ ͒ ͔ ͒ ͔ ͒ ͕ ͒ ͕ ͒ ͖ ͒ ͖ ͒ ͗ ͒ ͗ ͒ ͘ ͒ ͘ ͓ ͏ ͓ ͏ ͓ ͐ ͓ ͐ ͓ ͑ ͓ ͑ ͑ ͐͏ ͑ ͐͏ ͐ ͖͗ ͐ ͖͗ ͐ ͓͏ ͐ ͓͏ ͐ ͒͐ ͐ ͒͐ ͐ ͖͐ ͐ ͖͐ ͐ ͏͔ ͐ ͏͔ ͗ ͖ ͗ ͖ ͗ ͐ ͗ ͐ ͖ ͔ ͖ ͔ ͕ ͑ ͕ ͑ ͔ ͓ ͔ ͓ ͓ ͖ ͓ ͖ ͓ ͓ ͓ ͓ ͒ ͘ ͒ ͘ ͒ ͖ ͒ ͖ ͒ ͓ ͒ ͓ ͒ ͒ ͒ ͒ ͑ ͘ ͑ ͘ ͑ ͖ ͑ ͖ ͑ ͓ ͑ ͓ ͑ ͐ ͑ ͐ ͑ ͐ ͑ ͐ ͐ ͘ ͐ ͘ ͐ ͖ ͐ ͖ ͐ ͔ ͐ ͔ ͐ ͑ ͐ ͑ ͐ ͏ ͐ ͏ ͐ ͏ ͐ ͏ ͐ ͏ ͐ ͏ ͘ ͘ ͖ ͖ ͔ ͔ ͓ ͓ ͓ ͓ ͓ ͓ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͑ ͑ ͐ ͐ ͏ ͏ [ i b ϱ ‡ ‡ ϱ @( a i³ „ Ř ĺ æ Í æ Ė ī Ė ťƅ Lonca - R : R - GemOx : Censored : Median PFS, months (95% CI): Lonca - R : 6.14 (4.99, 8.11) R - GemOx : 4.73 (2.83, 5.55) Hazard Ratio (95% CI): 0.73 (0.57, 0.92) Two - sided p - value: 0.0084 Patients at risk:
LOTIS - 5 Topline Results 11 Difference from IRC assessment reflects lower censoring in investigator reported data Progression Free Survival by Investigator Assessment *Other reasons include starting NALT without confirmed PD, no postbaseline assessment, or consent withdrawal. IRC = Independent Review Committee, PFS = progression free survival; Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin; PD = progressive disease; NALT = new anti - lymphoma therapy ITT Population (N=420); Data cut off: February 16, 2026. # of Event/Censored Event/Censored Description Total 420 R - GEMOX N=210 LONCA - R N=210 306 (72.9%) 158 (75.2%) 148 (70.5%) Total # of Events 248 142 106 Disease Progression 58 16 42 Death 114 (27.1%) 52 (24.8%) 62 (29.5%) Total Censored 57 (13.6%) 18 (8.6%) 39 (18.6%) Ongoing 57 (13.6%) 34 (16.2%) 23 (11.0%) Censored due to other reasons* R - GemOx, % Lonca - R, % Event - free rate (95% CI) 32.6 (25.8, 39.6) 47.1 (40.0, 53.9) 6M 17.5 (12.2, 23.7) 29.1 (22.8, 35.8) 12M 13.3 (8.4, 19.3) 25.8 (19.6, 32.4) 18M 8.4 (4.1 14.7) 24.0 (17.9, 30.7) 24M “ Ė ı ôϙ ϼ ı ĺ IJ ť ē Ŝ Ͻ [ i b ϱ ‡ ͑ ͐͏ ͐ ͗͏ ͐ ͏͗ ͗ ͔ ͖ ͘ ͖ ͏ ͔ ͒ ͓ ͘ ͓ ͑ ͒ ͗ ͒ ͓ ͒ ͐ ͑ ͕ ͑ ͕ ͑ ͔ ͑ ͒ ͑ ͏ ͐ ͔ ͐ ͒ ͐ ͑ ͐ ͑ ͐ ͑ ͐ ͐ ͔ ͒ ͒ ͒ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͏ ͏ ͏ ͏ ͏ ͑ ͐͏ ͐ ͗͏ ͐ ͏͗ ͗ ͔ ͖ ͘ ͖ ͏ ͔ ͒ ͓ ͘ ͓ ͑ ͒ ͗ ͒ ͓ ͒ ͐ ͑ ͕ ͑ ͕ ͑ ͔ ͑ ͒ ͑ ͏ ͐ ͔ ͐ ͒ ͐ ͑ ͐ ͑ ͐ ͑ ͐ ͐ ͔ ͒ ͒ ͒ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͏ ͏ ͏ ͏ ͏ ‡ ϱ @( a i³ ͏ ͐ ͑ ͒ ͓ ͔ ͕ ͖ ͗ ͘ ͐ ͏ ͐ ͐ ͐ ͑ ͐ ͒ ͐ ͓ ͐ ͔ ͐ ͕ ͐ ͖ ͐ ͗ ͐ ͘ ͑ ͏ ͑ ͐ ͑ ͑ ͑ ͒ ͑ ͓ ͑ ͔ ͑ ͕ ͑ ͖ ͑ ͗ ͑ ͘ ͒ ͏ ͒ ͐ ͒ ͑ ͒ ͒ ͒ ͓ ͒ ͔ ͒ ͕ ͒ ͖ ͒ ͗ ͒ ͘ ͓ ͏ ͓ ͐ ͓ ͑ ͏ ͐ ͑ ͒ ͓ ͔ ͕ ͖ ͗ ͘ ͐ ͏ ͐ ͐ ͐ ͑ ͐ ͒ ͐ ͓ ͐ ͔ ͐ ͕ ͐ ͖ ͐ ͗ ͐ ͘ ͑ ͏ ͑ ͐ ͑ ͑ ͑ ͒ ͑ ͓ ͑ ͔ ͑ ͕ ͑ ͖ ͑ ͗ ͑ ͘ ͒ ͏ ͒ ͐ ͒ ͑ ͒ ͒ ͒ ͓ ͒ ͔ ͒ ͕ ͒ ͖ ͒ ͗ ͒ ͘ ͓ ͏ ͓ ͐ ͓ ͑ ͏ ϟ ͏ ͏ ϟ ͐ ͏ ϟ ͑ ͏ ϟ ͒ ͏ ϟ ͓ ͏ ϟ ͔ ͏ ϟ ͕ ͏ ϟ ͖ ͏ ϟ ͗ ͏ ϟ ͘ ͐ ϟ ͏ „ Ř ĺ æ Í æ Ė ī Ė ťƅ ť ϙ Ř Ė Ŝ ħ ϙϡ ͑ ͐͏ ͐ ͒͘ ͐ ͓͒ ͐ ͒͑ ͐ ͖͐ ͐ ͏͗ ͗ ͗ ͗ ͒ ͖ ͗ ͕ ͕ ͔ ͗ ͔ ͐ ͓ ͗ ͓ ͓ ͓ ͑ ͓ ͏ ͒ ͗ ͒ ͒ ͒ ͐ ͑ ͖ ͑ ͓ ͑ ͓ ͑ ͑ ͐ ͘ ͐ ͖ ͐ ͓ ͐ ͑ ͐ ͑ ͐ ͑ ͐ ͐ ͘ ͖ ͕ ͔ ͔ ͓ ͓ ͒ ͒ ͒ ͑ ͐ ͏ ͑ ͐͏ ͐ ͒͘ ͐ ͓͒ ͐ ͒͑ ͐ ͖͐ ͐ ͏͗ ͗ ͗ ͗ ͒ ͖ ͗ ͕ ͕ ͔ ͗ ͔ ͐ ͓ ͗ ͓ ͓ ͓ ͑ ͓ ͏ ͒ ͗ ͒ ͒ ͒ ͐ ͑ ͖ ͑ ͓ ͑ ͓ ͑ ͑ ͐ ͘ ͐ ͖ ͐ ͓ ͐ ͑ ͐ ͑ ͐ ͑ ͐ ͐ ͘ ͖ ͕ ͔ ͔ ͓ ͓ ͒ ͒ ͒ ͑ ͐ ͏ Lonca - R : R - GemOx : Censored : Median PFS, months (95% CI): Lonca - R : 5.49 (4.76, 7.89) R - GemOx : 3.02 (2.63, 4.96) Hazard Ratio (95% CI): 0.65 (0.51, 0.81) Nominal p - value: 0.0002 Patients at risk:
ťť ċ ť „ Ř ĺ î Ū è ť ϱ [ Ėı Ė ťϙ ‹ Ū Ř ŽĖ Ž Í īϙ ( Ŝ ť Ėı Í ť ô Ŝ ® Ė ť ēϙ b Ū ı æ ô Řϙ ĺ ċϙ ‹ Ūæ Ĥ ô è ť Ŝϙ Í ťϙ ‡ ĖŜ ħ ͏ ϟ ͏ ͏ ϟ ͑ ͏ ϟ ͓ ͏ ϟ ͕ ͏ ϟ ͗ ͐ ϟ ͏ ‹ Ū Ř ŽĖ Ž Í īϙ „ Ř ĺ æ Í æ Ė ī Ė ťƅ ť ϙ Ř Ė Ŝ ħ ϙϡ [ ib ϱ ‡ ‡ ϱ @( a i³ ͑ ͐ ͏ ͖ ͗ ͒ ͗ ͐ ͘ ͘ ͒ ͏ ͑ ͐ ͏ ͓ ͒ ͑ ͐ ͕ ͐ ͐ ͏ ͏ ͑ ͔ ͏ ͔ ͏ ͏ ͖ ͔ ͏ ͐ ͏͏ ͏ ͐ ͑ ͔ ͏ ͐ ͔ ͏ ͏ Lonca - R : R - GemOx : Censored : LOTIS - 5 Topline Results 12 Lonca - R time to treatment failure (PD, death, NALT or discontinuation) longer than that of R - GemOx Time to Treatment Failure IRC = Independent Review Committee, PFS = progression free survival; Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin; PD = progressive disease; NALT = new anti - lymphoma therapy ITT Population (N=420); Data cut off: February 16, 2026. Median, months: Lonca - R : 5.19 R - GemOx : 2.76 Hazard Ratio (95% CI): 0.64 (0.518, 0.786) Nominal p - value: <0.0001 Time (days) Patients at risk:
OS sensitivity analysis using IPCW method with adjustment for impact of NALT showed meaningful difference between treatment arms (HR=0.82, 95% CI: 0.72 - 0.93) LOTIS - 5 Topline Results 13 Key secondary efficacy endpoint of OS showed no detrimental effect Overall Survival Rate of NALT in test vs. control arm: 42.4% vs 57.6%; median time to NALT in test vs. control arm: 5.4 vs 3.7 months IPCW = Inverse Probability of Censoring Weighting; OS = overall survival; Lonca - R, loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin; NALT = new anti - lymphoma therapy ITT Population (N=420); Data cut off: February 16, 2026. Lonca - R : R - GemOx : Censored : Median OS, months (95% CI): Lonca - R : 12.19 (10.18, 15.05) R - GemOx : 12.16 (9.07, 15.38) Hazard Ratio (95% CI): 0.96 (0.75,1.23) Two - sided p - value: 0.7387 “ Ė ı ôϙ ϼ ı ĺ IJ ť ē Ŝ Ͻ [ i b ϱ ‡ ‡ ϱ @( a i³ ͏ ϟ ͏ ͏ ϟ ͐ ͏ ϟ ͑ ͏ ϟ ͒ ͏ ϟ ͓ ͏ ϟ ͔ ͏ ϟ ͕ ͏ ϟ ͖ ͏ ϟ ͗ ͏ ϟ ͘ ͐ ϟ ͏ „ Ř ĺ æ Í æ Ė ī Ė ťƅ ť ϙ Ř Ė Ŝ ħ ϙϡ ͑ ͐͏ ͑ ͐͏ ͐ ͖͘ ͐ ͖͘ ͐ ͓͗ ͐ ͓͗ ͐ ͖͏ ͐ ͖͏ ͐ ͔͔ ͐ ͔͔ ͐ ͓͑ ͐ ͓͑ ͐ ͑͘ ͐ ͑͘ ͐ ͑͑ ͐ ͑͑ ͐ ͕͐ ͐ ͕͐ ͐ ͏͕ ͐ ͏͕ ͐ ͏͐ ͐ ͏͐ ͘ ͔ ͘ ͔ ͘ ͑ ͘ ͑ ͗ ͒ ͗ ͒ ͖ ͕ ͖ ͕ ͕ ͗ ͕ ͗ ͕ ͓ ͕ ͓ ͔ ͕ ͔ ͕ ͔ ͒ ͔ ͒ ͓ ͕ ͓ ͕ ͓ ͓ ͓ ͓ ͓ ͑ ͓ ͑ ͒ ͖ ͒ ͖ ͒ ͓ ͒ ͓ ͒ ͑ ͒ ͑ ͑ ͗ ͑ ͗ ͑ ͕ ͑ ͕ ͑ ͒ ͑ ͒ ͑ ͒ ͑ ͒ ͑ ͑ ͑ ͑ ͑ ͏ ͑ ͏ ͐ ͗ ͐ ͗ ͐ ͔ ͐ ͔ ͐ ͓ ͐ ͓ ͐ ͓ ͐ ͓ ͐ ͓ ͐ ͓ ͐ ͒ ͐ ͒ ͐ ͐ ͐ ͐ ͐ ͏ ͐ ͏ ͘ ͘ ͗ ͗ ͗ ͗ ͓ ͓ ͒ ͒ ͒ ͒ ͒ ͒ ͑ ͑ ͏ ͏ ͏ ͏ ͐ ͐ ͑ ͑ ͒ ͒ ͓ ͓ ͔ ͔ ͕ ͕ ͖ ͖ ͗ ͗ ͘ ͘ ͐ ͏ ͐ ͏ ͐ ͐ ͐ ͐ ͐ ͑ ͐ ͑ ͐ ͒ ͐ ͒ ͐ ͓ ͐ ͓ ͐ ͔ ͐ ͔ ͐ ͕ ͐ ͕ ͐ ͖ ͐ ͖ ͐ ͗ ͐ ͗ ͐ ͘ ͐ ͘ ͑ ͏ ͑ ͏ ͑ ͐ ͑ ͐ ͑ ͑ ͑ ͑ ͑ ͒ ͑ ͒ ͑ ͓ ͑ ͓ ͑ ͔ ͑ ͔ ͑ ͕ ͑ ͕ ͑ ͖ ͑ ͖ ͑ ͗ ͑ ͗ ͑ ͘ ͑ ͘ ͒ ͏ ͒ ͏ ͒ ͐ ͒ ͐ ͒ ͑ ͒ ͑ ͒ ͒ ͒ ͒ ͒ ͓ ͒ ͓ ͒ ͔ ͒ ͔ ͒ ͕ ͒ ͕ ͒ ͖ ͒ ͖ ͒ ͗ ͒ ͗ ͒ ͘ ͒ ͘ ͓ ͏ ͓ ͏ ͓ ͐ ͓ ͐ ͓ ͑ ͓ ͑ ͓ ͒ ͓ ͒ ͓ ͓ ͓ ͓ ͓ ͔ ͓ ͔ ͓ ͕ ͓ ͕ ͓ ͖ ͓ ͖ ͑ ͐͏ ͑ ͐͏ ͑ ͏͗ ͑ ͏͗ ͐ ͔͘ ͐ ͔͘ ͐ ͓͗ ͐ ͓͗ ͐ ͖͏ ͐ ͖͏ ͐ ͔͗ ͐ ͔͗ ͐ ͓͕ ͐ ͓͕ ͐ ͒͗ ͐ ͒͗ ͐ ͒͑ ͐ ͒͑ ͐ ͔͑ ͐ ͔͑ ͐ ͓͐ ͐ ͓͐ ͐ ͏͔ ͐ ͏͔ ͘ ͘ ͘ ͘ ͗ ͕ ͗ ͕ ͖ ͘ ͖ ͘ ͖ ͕ ͖ ͕ ͖ ͐ ͖ ͐ ͖ ͏ ͖ ͏ ͕ ͘ ͕ ͘ ͕ ͕ ͕ ͕ ͔ ͕ ͔ ͕ ͔ ͒ ͔ ͒ ͓ ͗ ͓ ͗ ͓ ͒ ͓ ͒ ͒ ͕ ͒ ͕ ͒ ͒ ͒ ͒ ͑ ͗ ͑ ͗ ͑ ͗ ͑ ͗ ͑ ͕ ͑ ͕ ͑ ͓ ͑ ͓ ͑ ͑ ͑ ͑ ͑ ͏ ͑ ͏ ͐ ͗ ͐ ͗ ͐ ͒ ͐ ͒ ͐ ͐ ͐ ͐ ͖ ͖ ͕ ͕ ͔ ͔ ͔ ͔ ͓ ͓ ͓ ͓ ͓ ͓ ͒ ͒ ͐ ͐ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ # of Event/Censored Event/Censored Description Total 420 R - GemOx N=210 Lonca - R N=210 170 91 (43.3%) 79 (37.6%) Censored 250 119 (56.7) 131 (62.4) Deaths 420 210 210 Total Patients at risk: Patients at risk:
14 Lonca-R (N=210) R-GemOx (N=210) ORR: 58.1% (n=122) ORR: 45.2% (n=95) PR: 18.6% (n=39) CR: 39.5% (n=83) PR: 18.6% (n=39) CR: 26.7% (n=56) LOTIS - 5 Topline Results 14 Improvement in ORR and CR demonstrated with ZYNLONTA plus rituximab vs. R - GemOx Overall Response Rate by IRC Percentages may not add due to rounding. In the Lonca - R vs .R - Gemox arm: Median time to best overall response: 44 days for both arms; Median time to complete response: 49 vs. 65 days. CR = complete response; Lonca - R = loncastuximab tesirine - lpyl with rituximab; PR = partial response; R - GemOx = rituximab + gemcitabine + oxaliplatin. ITT Population (N=420); Data cut off: February 16, 2026.
LOTIS - 5 Topline Results 15 At 24 months, 48.5% of patients achieving CR remained in CR with ZYNLONTA plus rituximab vs.16.7% with R - GemOx Duration of Response/Complete Response by IRC Lonca - R = loncastuximab tesirine - lpyl with rituximab; NE = not estimable; R - GemOx = rituximab + gemcitabine + oxaliplatin. Responders only for duration of response (DOR) and complete responders only for duration of complete response (DOCR) Data cut off: February 16, 2026. Duration of Response Duration of Complete Response “ Ė ı ôϙ ϼ ı ĺ IJ ť ē Ŝ Ͻ [ i b ϱ ‡ ‡ ϱ @( a i³ ͏ ϟ ͏ ͏ ϟ ͐ ͏ ϟ ͑ ͏ ϟ ͒ ͏ ϟ ͓ ͏ ϟ ͔ ͏ ϟ ͕ ͏ ϟ ͖ ͏ ϟ ͗ ͏ ϟ ͘ ͐ ϟ ͏ „ Ř ĺ æ Í æ Ė ī Ė ťƅ ť ϙ Ř Ė Ŝ ħ ϙϡ ͐ ͑͑ ͘ ͔ ͐ ͑͑ ͘ ͔ ͏ ͏ ͐ ͕͐ ͘ ͏ ͐ ͕͐ ͘ ͏ ͐ ͐ ͐ ͏͗ ͖ ͑ ͐ ͏͗ ͖ ͑ ͑ ͑ ͘ ͔ ͕ ͑ ͘ ͔ ͕ ͑ ͒ ͒ ͗ ͘ ͔ ͕ ͗ ͘ ͔ ͕ ͓ ͓ ͖ ͗ ͓ ͘ ͖ ͗ ͓ ͘ ͔ ͔ ͖ ͑ ͓ ͑ ͖ ͑ ͓ ͑ ͕ ͕ ͕ ͕ ͒ ͘ ͕ ͕ ͒ ͘ ͖ ͖ ͔ ͖ ͒ ͔ ͔ ͖ ͒ ͔ ͗ ͗ ͔ ͑ ͒ ͐ ͔ ͑ ͒ ͐ ͘ ͘ ͓ ͔ ͑ ͖ ͓ ͔ ͑ ͖ ͐ ͏ ͐ ͏ ͒ ͘ ͑ ͔ ͒ ͘ ͑ ͔ ͐ ͐ ͐ ͐ ͒ ͘ ͑ ͓ ͒ ͘ ͑ ͓ ͐ ͑ ͐ ͑ ͒ ͓ ͑ ͐ ͒ ͓ ͑ ͐ ͐ ͒ ͐ ͒ ͒ ͒ ͐ ͖ ͒ ͒ ͐ ͖ ͐ ͓ ͐ ͓ ͒ ͒ ͐ ͕ ͒ ͒ ͐ ͕ ͐ ͔ ͐ ͔ ͑ ͖ ͐ ͑ ͑ ͖ ͐ ͑ ͐ ͕ ͐ ͕ ͑ ͔ ͐ ͏ ͑ ͔ ͐ ͏ ͐ ͖ ͐ ͖ ͑ ͒ ͐ ͏ ͑ ͒ ͐ ͏ ͐ ͗ ͐ ͗ ͑ ͐ ͐ ͏ ͑ ͐ ͐ ͏ ͐ ͘ ͐ ͘ ͐ ͖ ͗ ͐ ͖ ͗ ͑ ͏ ͑ ͏ ͐ ͖ ͔ ͐ ͖ ͔ ͑ ͐ ͑ ͐ ͐ ͕ ͑ ͐ ͕ ͑ ͑ ͑ ͑ ͑ ͐ ͒ ͑ ͐ ͒ ͑ ͑ ͒ ͑ ͒ ͐ ͑ ͑ ͐ ͑ ͑ ͑ ͓ ͑ ͓ ͐ ͏ ͏ ͐ ͏ ͏ ͑ ͔ ͑ ͔ ͐ ͏ ͏ ͐ ͏ ͏ ͑ ͕ ͑ ͕ ͐ ͏ ͏ ͐ ͏ ͏ ͑ ͖ ͑ ͖ ͗ ͏ ͗ ͏ ͑ ͗ ͑ ͗ ͕ ͏ ͕ ͏ ͑ ͘ ͑ ͘ ͓ ͏ ͓ ͏ ͒ ͏ ͒ ͏ ͓ ͏ ͓ ͏ ͒ ͐ ͒ ͐ ͓ ͏ ͓ ͏ ͒ ͑ ͒ ͑ ͓ ͏ ͓ ͏ ͒ ͒ ͒ ͒ ͒ ͏ ͒ ͏ ͒ ͓ ͒ ͓ ͒ ͏ ͒ ͏ ͒ ͔ ͒ ͔ ͒ ͏ ͒ ͏ ͒ ͕ ͒ ͕ ͒ ͏ ͒ ͏ ͒ ͖ ͒ ͖ ͒ ͏ ͒ ͏ ͒ ͗ ͒ ͗ ͑ ͏ ͑ ͏ ͒ ͘ ͒ ͘ ͏ ͏ ͏ ͏ ͓ ͏ ͓ ͏ “ Ė ı ôϙ ϼ ı ĺ IJ ť ē Ŝ Ͻ [ i b ϱ ‡ ‡ ϱ @( a i³ ͏ ϟ ͏ ͏ ϟ ͐ ͏ ϟ ͑ ͏ ϟ ͒ ͏ ϟ ͓ ͏ ϟ ͔ ͏ ϟ ͕ ͏ ϟ ͖ ͏ ϟ ͗ ͏ ϟ ͘ ͐ ϟ ͏ „ Ř ĺ æ Í æ Ė ī Ė ťƅ ť ϙ Ř Ė Ŝ ħ ϙϡ ͗ ͒ ͗ ͒ ͔ ͕ ͔ ͕ ͏ ͏ ͖ ͘ ͖ ͘ ͔ ͓ ͔ ͓ ͐ ͐ ͖ ͖ ͖ ͖ ͓ ͘ ͓ ͘ ͑ ͑ ͖ ͑ ͖ ͑ ͓ ͐ ͓ ͐ ͒ ͒ ͖ ͏ ͖ ͏ ͒ ͘ ͒ ͘ ͓ ͓ ͕ ͓ ͕ ͓ ͒ ͔ ͒ ͔ ͔ ͔ ͕ ͐ ͕ ͐ ͒ ͏ ͒ ͏ ͕ ͕ ͔ ͖ ͔ ͖ ͑ ͘ ͑ ͘ ͖ ͖ ͔ ͐ ͔ ͐ ͑ ͕ ͑ ͕ ͗ ͗ ͓ ͖ ͓ ͖ ͑ ͒ ͑ ͒ ͘ ͘ ͓ ͐ ͓ ͐ ͑ ͒ ͑ ͒ ͐ ͏ ͐ ͏ ͒ ͗ ͒ ͗ ͑ ͐ ͑ ͐ ͐ ͐ ͐ ͐ ͒ ͕ ͒ ͕ ͑ ͏ ͑ ͏ ͐ ͑ ͐ ͑ ͒ ͑ ͒ ͑ ͐ ͕ ͐ ͕ ͐ ͒ ͐ ͒ ͒ ͐ ͒ ͐ ͐ ͒ ͐ ͒ ͐ ͓ ͐ ͓ ͒ ͏ ͒ ͏ ͐ ͒ ͐ ͒ ͐ ͔ ͐ ͔ ͑ ͒ ͑ ͒ ͐ ͐ ͐ ͐ ͐ ͕ ͐ ͕ ͑ ͐ ͑ ͐ ͘ ͘ ͐ ͖ ͐ ͖ ͑ ͐ ͑ ͐ ͗ ͗ ͐ ͗ ͐ ͗ ͐ ͗ ͐ ͗ ͕ ͕ ͐ ͘ ͐ ͘ ͐ ͕ ͐ ͕ ͓ ͓ ͑ ͏ ͑ ͏ ͐ ͔ ͐ ͔ ͑ ͑ ͑ ͐ ͑ ͐ ͐ ͓ ͐ ͓ ͐ ͐ ͑ ͑ ͑ ͑ ͐ ͑ ͐ ͑ ͏ ͏ ͑ ͒ ͑ ͒ ͐ ͐ ͐ ͐ ͏ ͏ ͑ ͓ ͑ ͓ ͘ ͘ ͏ ͏ ͑ ͔ ͑ ͔ ͘ ͘ ͏ ͏ ͑ ͕ ͑ ͕ ͘ ͘ ͏ ͏ ͑ ͖ ͑ ͖ ͗ ͗ ͏ ͏ ͑ ͗ ͑ ͗ ͓ ͓ ͏ ͏ ͑ ͘ ͑ ͘ ͓ ͓ ͏ ͏ ͒ ͏ ͒ ͏ ͓ ͓ ͏ ͏ ͒ ͐ ͒ ͐ ͒ ͒ ͏ ͏ ͒ ͑ ͒ ͑ ͒ ͒ ͏ ͏ ͒ ͒ ͒ ͒ ͒ ͒ ͏ ͏ ͒ ͓ ͒ ͓ ͒ ͒ ͏ ͏ ͒ ͔ ͒ ͔ ͒ ͒ ͏ ͏ ͒ ͕ ͒ ͕ ͒ ͒ ͏ ͏ ͒ ͖ ͒ ͖ ͒ ͒ ͏ ͏ ͒ ͗ ͒ ͗ ͑ ͑ ͏ ͏ ͒ ͘ ͒ ͘ ͏ ͏ ͏ ͏ ͓ ͏ ͓ ͏ Median DOR, months (95% CI) Lonca - R : 9.20 (7.23, 12.78) R - GemOx : 7.66 (5.68, 10.38) Hazard Ratio (95% CI): 0.71 (0.50, 1.02) Median DoCR , months (95% CI) Lonca - R : 16.82 (9.46, NE) R - GemOx : 12.25 (7.66, 16.49) Hazard Ratio (95% CI): 0.57 (0.35, 0.94) Lonca - R : R - GemOx : Censored : Lonca - R : R - GemOx : Censored : Patients at risk: Patients at risk:
LOTIS - 5 Topline Results 16 Summary of key results LOTIS - 5: Safety SAE = serious adverse event; TEAE = treatment emergent adverse event Data cut off: February 16, 2026. Overall TEAE rates similar between arms Similar rates of overall Grade ≥3 TEAEs >5% were observed across both arms – Hematologic TEAEs were higher in the control arm – Infection, hepatoxicity and edema/effusion were higher in the test arm SAEs, TEAEs leading to study drug withdrawal and Grade 5 events were higher in the test arm – Majority of Grade 5 TEAEs in test arm occurred in patients aged 75 years or older Rates of TEAEs impacted by longer overall TEAE observation time in test vs control arm – Difference primarily driven by higher rate of and earlier switching to subsequent therapies in control arm
LOTIS - 5 Topline Results 17 Overall Summary of Treatment Emergent Adverse Events TEAE reporting window defined as 105 days after last dose of study treatment or start of NALT, whichever is earlier. Median TEA E follow - up time: 3.9 months on LONCA - R and 2.5 months on R - GEMOX TEAE = treatment emergent adverse events; Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin; NALT = new anti - lymphoma therapy; Treated population (patients who received at least one dose of any study drug), N=401; Data cut off: February 16, 2026. R - GEMOX (N=197) n (%) LONCA - R (N=204) n (%) 192 (97.5%) 201 (98.5%) Patients with any TEAE 150 (76.1%) 151 (74.0%) Patients with any grade 3 or higher TEAE 178 (90.4%) 175 (85.8%) Patients with any TEAE related to any study drug 131 (66.5%) 132 (64.7%) Patients with any TEAE leading to any study drug dose delay or reduction 18 (9.1%) 52 (25.5%) Patients with any TEAE leading to any study drug withdrawal 68 (34.5%) 100 (49.0%) Patients with any serious TEAE 44 (22.3%) 61 (29.9%) Patients with any drug - related serious TEAE 9 (4.6%) 27 (13.2%) Patients with any Grade 5 TEAE 2 (1.0%) 6 (2.9%) Patients with any drug - related Grade 5 TEAE
R - GemOx (N=197), n (%) Lonca - R (N=204), n (%) Grouped Term / Preferred Term 150 (76.1%) 151 (74.0%) Patients with any grade 3 or higher TEAE 117 (59.4 % ) 83 (40.7 % ) Blood and lymphatic system disorders (SOC) 67 (34.0%) 52 (25.5%) Neutropenia 65 (33.0%) 25 (12.3%) Thrombocytopenia 32 (16.2%) 23 (11.3%) Anaemia 21 (10.7%) 20 (9.8%) Leukopenia 15 (7.6%) 20 (9.8%) Lymphopenia 31 (15.7 % ) 50 (24.5 % ) Infections and infestations (SOC) 11 (5.6%) 26 (12.7%) Pneumonia 16 (8.1 % ) 35 (17.2 % ) Hepatotoxicity (AESI) 9 (4.6%) 28 (13.7%) Gamma - glutamyltransferase increased 1 (0.5 % ) 15 (7.4 % ) Oedema / Effusion (AESI ) 0 11 (5.4 % ) Pleural effusion LOTIS - 5 Topline Results 18 Grade 3 or Higher Treatment Emergent Adverse Events >5% Group Term is based on either SOC or AESI category TEAE reporting window defined as 105 days or upon switching therapy, TEAE = treatment emergent adverse events; SOC = system o rga n class; AESI = adverse event of special interest; Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin; Treated population, N=401; Data cut off: February 16, 2026.
LOTIS - 5 Topline Results 19 Rates of TEAEs impacted by longer overall TEAE observation time in test vs control arm Time from First Dose to Key Safety Events* *Key safety events defined as any Grade ≥3 TEAE; serious TEAE, or TEAE leading to study drug withdrawal; If TEAE occurred, ce nso r at the last dose +105 days, or start of NALT or death due to other reasons than TEAE, whichever is earlier. TEAE = treatment emergent adverse event; NALT = new anti - lymphoma therapy; Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin; Treated population, N=401; Data cut off: February 16, 2026. Longer time from first dose to key safety events, reflecting more event - free time in favor of test arm Longer overall TEAE observation time leading to more reported events in test arm IJ Í ī ƅ ŜĖ Ŝϙ ‹ ť Í Ř ťϙ ‡ ô ī Í ť Ė Ž ôϙ " Í ƅ ͏ ϟ ͏ ͏ ϟ ͑ ͏ ϟ ͓ ͏ ϟ ͕ ͏ ϟ ͗ ͐ ϟ ͏ ‹ Ū Ř ŽĖ Ž Í īϙ „ Ř ĺ æ Í æ Ė ī Ė ťƅ ť ϙ Ř Ė Ŝ ħ ϙϡ [ ib ϱ ‡ ‡ ϱ @( a i³ ͑ ͏ ͓ ͕ ͖ ͑ ͖ ͐ ͐ ͘ ͖ ͒ ͗ ͐ ͐ ͏ ͏ ͐ ͏ ͏ ͑ ͏ ͏ ͒ ͏ ͏ „ Ř ĺ î Ū è ť ϱ [ Ėı Ė ťϙ ‹ Ū Ř ŽĖ Ž Í īϙ ( Ŝ ť Ėı Í ť ô Ŝ ® Ė ť ēϙ b Ū ı æ ô Řϙ ĺ ċϙ ‹ Ūæ Ĥ ô è ť Ŝϙ Í ťϙ ‡ ĖŜ ħ Lonca - R : R - GemOx : Censored : Median, months: Lonca - R : 2.10 R - GemOx : 0.92 Hazard Ratio (95% CI): 0.662 (0.528, 0.831) Nominal p - value: 0.0003 Time (days) Patients at risk:
LOTIS - 5 Topline Results 20 Cause of Grade 5 Treatment Emergent Adverse Events a: One patient with bacterial inguinal infection and one patient gastrointestinal infection; b: two patients with general det eri oration due to disease progression; c: one patient died in sleep in setting of progressive disease and one patient had previous cardiac history and diabetes; TEAE repor tin g window defined as 105 days after the last dose of study treatment or start of NALT , whichever is earlier SOC = system organ class; TEAE = treatment emergent adverse event; NALT = new anti - lymphoma therapy. Treated population, N=401; Data cut off: February 16, 2026. R - GemOx (N=9) Lonca - R (N=27) SOC Term/ Preferred Term 5 15 Infections and Infestations 1 9 Pneumonia 4 3 Sepsis 0 1 COVID - 19 0 2 Other Infection a 2 4 Cardiac Disorders 1 2 Cardiac failure 0 1 Cardio - respiratory arrest 1 1 Myocardial infarction 1 4 General Disorders 0 2 General physical health deterioration b 0 2 Sudden Cardiac Arrest c 1 0 Unknown 0 1 Injury, Poisoning and Procedural Complications: Uterine Perforation 1 1 Nervous System Disorders 0 1 Cerebrovascular accident 1 0 Cerebral haemorrhage 0 1 Renal and Urinary Disorders: AKI 0 1 Respiratory, Thoracic and Mediastinal Disorders: Respiratory Failure Note: Median age for patients with Grade 5 TEAEs 76 vs. 74 in test vs. control arm R - GEMOX N=9 LONCA - R N=27 36.7% 40.2% % of all treated patients ≥75 years of age 22% (2/9) 59% (16/27) % of all Grade 5 TEAEs in patients ≥75 years of age 2 cycles (1 - 8) 4 cycles (1 - 7) Median treatment exposure for Grade 5 TEAEs
LOTIS - 5 Topline Results 21 Upcoming Potential Milestones → Pre - sBLA meeting (Aug) → sBLA filing (Q4 2026) → Data presentation (Q4 26) → Compendia inclusion (1H27) → Confirmatory approval (2H 27) ZYNLONTA LOTIS - 5 → Data presentation (Q4 26) → Compendia inclusion (1H 27) → Assess regulatory strategy ZYNLONTA LOTIS - 7 → Data presentation (Q4 26) → Compendia inclusion (1H 27) → Assess regulatory strategy Marginal Zone Lymphoma (MZL) → Data presentation (Q2 27) → Compendia update (2H 27) → Assess regulatory strategy Follicular Lymphoma (FL)
Our sincere thanks … to the patients, caregivers, investigators and clinical trial sites for their participation in LOTIS - 5 and to the ADC Therapeutics team who contributed to this important trial.
Appendix
LOTIS - 5 Topline Results 24 Drug Exposure (Safety Population N=401) *Dose intensity is defined by total dose divided by treatment duration. Relative dose intensity is defined as actual dose int ens ity divided by planned dose intensity, reflecting the extent of dose reduction and dose delay during treatment. Treated population, N=401; Data cut off: February 16, 2026. R - GemOx (N=197) Lonca - R (N=204) Characteristic Number of Cycles 5 5 Median (1,8) (1,8) Range Duration of Treatment (Days) 77 107 Median (9, 233) (7, 492) Range 92% for rituximab 89% for gemcitabine 87% for oxaliplatin 96% for ZYNLONTA only Relative Dose Intensity*
LOTIS - 5 Topline Results 25 Forest Plot of Progression Free Survival by IRC Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin. ITT population, N=420; IRC = independent review committee Data cut off: February 16, 2026. 25 In favor of Lonca - R In favor of R - GemOx
LOTIS - 5 Topline Results 26 Prespecified Analysis: Progression Free Survival by IRC by Age Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin. Treated population, N=401; Data cut off: February 16, 2026 ≥ 75 years old ͏ ͏ ͐ ͐ ͑ ͑ ͒ ͒ ͓ ͓ ͔ ͔ ͕ ͕ ͖ ͖ ͗ ͗ ͘ ͘ ͐ ͏ ͐ ͏ ͐ ͐ ͐ ͐ ͐ ͑ ͐ ͑ ͐ ͒ ͐ ͒ ͐ ͓ ͐ ͓ ͐ ͔ ͐ ͔ ͐ ͕ ͐ ͕ ͐ ͖ ͐ ͖ ͐ ͗ ͐ ͗ ͐ ͘ ͐ ͘ ͑ ͏ ͑ ͏ ͑ ͐ ͑ ͐ ͑ ͑ ͑ ͑ ͑ ͒ ͑ ͒ ͑ ͓ ͑ ͓ ͑ ͔ ͑ ͔ ͑ ͕ ͑ ͕ ͑ ͖ ͑ ͖ ͑ ͗ ͑ ͗ ͑ ͘ ͑ ͘ ͒ ͏ ͒ ͏ ͒ ͐ ͒ ͐ ͒ ͑ ͒ ͑ ͒ ͒ ͒ ͒ ͒ ͓ ͒ ͓ ͒ ͔ ͒ ͔ ͒ ͕ ͒ ͕ ͒ ͖ ͒ ͖ ͒ ͗ ͒ ͗ ͒ ͘ ͒ ͘ ͓ ͏ ͓ ͏ ͓ ͐ ͓ ͐ ͓ ͑ ͓ ͑ “ Ė ı ôϙ ϼ ı ĺ IJ ť ē Ŝ Ͻ ͏ ϟ ͏ ͏ ϟ ͐ ͏ ϟ ͑ ͏ ϟ ͒ ͏ ϟ ͓ ͏ ϟ ͔ ͏ ϟ ͕ ͏ ϟ ͖ ͏ ϟ ͗ ͏ ϟ ͘ ͐ ϟ ͏ „ Ř ĺ æ Í æ Ė ī Ė ťƅ ť ϙ Ř Ė Ŝ ħ ϙϡ [ ib ϱ ‡ ͐ ͒ ͐ ͐ ͒ ͐ ͐ ͐ ͒ ͐ ͐ ͒ ͕ ͖ ͕ ͖ ͔ ͒ ͔ ͒ ͓ ͗ ͓ ͗ ͓ ͓ ͓ ͓ ͒ ͔ ͒ ͔ ͒ ͏ ͒ ͏ ͑ ͔ ͑ ͔ ͑ ͔ ͑ ͔ ͑ ͑ ͑ ͑ ͑ ͏ ͑ ͏ ͐ ͗ ͐ ͗ ͐ ͔ ͐ ͔ ͐ ͓ ͐ ͓ ͐ ͓ ͐ ͓ ͐ ͒ ͐ ͒ ͘ ͘ ͗ ͗ ͖ ͖ ͖ ͖ ͕ ͕ ͕ ͕ ͑ ͑ ͐ ͐ ͐ ͐ ͐ ͐ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ‡ ϱ @( a i³ ͐ ͑ ͒ ͐ ͑ ͒ ͐ ͐ ͑ ͐ ͐ ͑ ͗ ͓ ͗ ͓ ͗ ͐ ͗ ͐ ͖ ͒ ͖ ͒ ͕ ͕ ͕ ͕ ͔ ͕ ͔ ͕ ͔ ͔ ͔ ͔ ͔ ͑ ͔ ͑ ͓ ͑ ͓ ͑ ͒ ͘ ͒ ͘ ͒ ͓ ͒ ͓ ͒ ͒ ͒ ͒ ͑ ͘ ͑ ͘ ͑ ͖ ͑ ͖ ͑ ͔ ͑ ͔ ͑ ͔ ͑ ͔ ͑ ͑ ͑ ͑ ͑ ͏ ͑ ͏ ͐ ͖ ͐ ͖ ͐ ͕ ͐ ͕ ͐ ͕ ͐ ͕ ͐ ͔ ͐ ͔ ͐ ͒ ͐ ͒ ͐ ͐ ͐ ͐ ͗ ͗ ͖ ͖ ͖ ͖ ͖ ͖ ͕ ͕ ͔ ͔ ͓ ͓ ͓ ͓ ͓ ͓ ͓ ͓ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͑ ͑ ͐ ͐ ͏ ͏ Median PFS, months (95% CI): Lonca - R : 8.28 (5.13, 10.18) R - GemOx : 3.15 (2.53, 5.59) Hazard Ratio (95% CI) : 0.55 (0.41, 0.76) Lonca - R : R - GemOx : Censored : < 75 years old “ Ė ı ôϙ ϼ ı ĺ IJ ť ē Ŝ Ͻ ͏ ϟ ͏ ͏ ϟ ͐ ͏ ϟ ͑ ͏ ϟ ͒ ͏ ϟ ͓ ͏ ϟ ͔ ͏ ϟ ͕ ͏ ϟ ͖ ͏ ϟ ͗ ͏ ϟ ͘ ͐ ϟ ͏ „ Ř ĺ æ Í æ Ė ī Ė ťƅ ť ϙ Ř Ė Ŝ ħ ϙϡ [ ib ϱ ‡ ‡ ϱ @( a i³ ͗ ͖ ͗ ͖ ͖ ͔ ͖ ͔ ͔ ͕ ͔ ͕ ͔ ͏ ͔ ͏ ͓ ͓ ͓ ͓ ͒ ͘ ͒ ͘ ͒ ͐ ͒ ͐ ͑ ͕ ͑ ͕ ͑ ͒ ͑ ͒ ͑ ͏ ͑ ͏ ͐ ͔ ͐ ͔ ͐ ͒ ͐ ͒ ͐ ͐ ͐ ͐ ͐ ͏ ͐ ͏ ͐ ͏ ͐ ͏ ͘ ͘ ͗ ͗ ͖ ͖ ͖ ͖ ͖ ͖ ͔ ͔ ͔ ͔ ͓ ͓ ͓ ͓ ͓ ͓ ͓ ͓ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͑ ͑ ͐ ͐ ͏ ͏ ͖ ͘ ͖ ͘ ͕ ͗ ͕ ͗ ͓ ͔ ͓ ͔ ͒ ͕ ͒ ͕ ͒ ͑ ͒ ͑ ͑ ͖ ͑ ͖ ͑ ͐ ͑ ͐ ͑ ͏ ͑ ͏ ͐ ͗ ͐ ͗ ͐ ͕ ͐ ͕ ͐ ͓ ͐ ͓ ͐ ͓ ͐ ͓ ͐ ͑ ͐ ͑ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͗ ͗ ͕ ͕ ͔ ͔ ͓ ͓ ͓ ͓ ͓ ͓ ͓ ͓ ͒ ͒ ͑ ͑ ͐ ͐ ͐ ͐ ͐ ͐ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͐ ͐ ͑ ͑ ͒ ͒ ͓ ͓ ͔ ͔ ͕ ͕ ͖ ͖ ͗ ͗ ͘ ͘ ͐ ͏ ͐ ͏ ͐ ͐ ͐ ͐ ͐ ͑ ͐ ͑ ͐ ͒ ͐ ͒ ͐ ͓ ͐ ͓ ͐ ͔ ͐ ͔ ͐ ͕ ͐ ͕ ͐ ͖ ͐ ͖ ͐ ͗ ͐ ͗ ͐ ͘ ͐ ͘ ͑ ͏ ͑ ͏ ͑ ͐ ͑ ͐ ͑ ͑ ͑ ͑ ͑ ͒ ͑ ͒ ͑ ͓ ͑ ͓ ͑ ͔ ͑ ͔ ͑ ͕ ͑ ͕ ͑ ͖ ͑ ͖ ͑ ͗ ͑ ͗ ͑ ͘ ͑ ͘ ͒ ͏ ͒ ͏ ͒ ͐ ͒ ͐ ͒ ͑ ͒ ͑ Median PFS, months (95% CI): Lonca - R : 5.22 (3.81, 6.60) R - GemOx : 5.13 (3.98, 7.85) Hazard Ratio (95% CI) : 1.07 (0.72, 1.57) Patients at risk: Patients at risk:
LOTIS - 5 Topline Results 27 Prespecified Analysis: Overall Survival by Age Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin. Treated population, N=401; Data cut off: February 16, 2026. ‡ ϱ @( a i³ ͏ ϟ ͏ ͏ ϟ ͐ ͏ ϟ ͑ ͏ ϟ ͒ ͏ ϟ ͓ ͏ ϟ ͔ ͏ ϟ ͕ ͏ ϟ ͖ ͏ ϟ ͗ ͏ ϟ ͘ ͐ ϟ ͏ „ Ř ĺ æ Í æ Ė ī Ė ťƅ ť ϙ Ř Ė Ŝ ħ ϙϡ [ i b ϱ ‡ ͐ ͒ ͐ ͐ ͒ ͐ ͐ ͑ ͑ ͐ ͑ ͑ ͐ ͐ ͔ ͐ ͐ ͔ ͐ ͏ ͗ ͐ ͏ ͗ ͘ ͕ ͘ ͕ ͗ ͗ ͗ ͗ ͗ ͐ ͗ ͐ ͖ ͓ ͖ ͓ ͕ ͘ ͕ ͘ ͕ ͑ ͕ ͑ ͔ ͘ ͔ ͘ ͔ ͔ ͔ ͔ ͔ ͒ ͔ ͒ ͓ ͖ ͓ ͖ ͓ ͒ ͓ ͒ ͒ ͗ ͒ ͗ ͒ ͔ ͒ ͔ ͒ ͐ ͒ ͐ ͑ ͗ ͑ ͗ ͑ ͑ ͑ ͑ ͑ ͑ ͑ ͑ ͑ ͏ ͑ ͏ ͐ ͗ ͐ ͗ ͐ ͕ ͐ ͕ ͐ ͕ ͐ ͕ ͐ ͒ ͐ ͒ ͐ ͐ ͐ ͐ ͐ ͏ ͐ ͏ ͐ ͏ ͐ ͏ “ Ė ı ôϙ ϼ ı ĺ IJ ť ē Ŝ Ͻ ͘ ͘ ͘ ͘ ͗ ͗ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͔ ͒ ͒ ͑ ͑ ͑ ͑ ͑ ͑ ͑ ͑ ͏ ͏ ͐ ͑ ͒ ͐ ͑ ͒ ͐ ͑ ͐ ͐ ͑ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͏ ͒ ͐ ͏ ͒ ͘ ͘ ͘ ͘ ͘ ͐ ͘ ͐ ͗ ͖ ͗ ͖ ͗ ͕ ͗ ͕ ͗ ͓ ͗ ͓ ͗ ͐ ͗ ͐ ͖ ͓ ͖ ͓ ͕ ͖ ͕ ͖ ͕ ͔ ͕ ͔ ͔ ͖ ͔ ͖ ͔ ͐ ͔ ͐ ͓ ͘ ͓ ͘ ͓ ͖ ͓ ͖ ͓ ͕ ͓ ͕ ͓ ͕ ͓ ͕ ͓ ͓ ͓ ͓ ͒ ͗ ͒ ͗ ͒ ͖ ͒ ͖ ͒ ͒ ͒ ͒ ͑ ͘ ͑ ͘ ͑ ͓ ͑ ͓ ͑ ͑ ͑ ͑ ͐ ͘ ͐ ͘ ͐ ͘ ͐ ͘ ͐ ͗ ͐ ͗ ͐ ͖ ͐ ͖ ͐ ͔ ͐ ͔ ͐ ͔ ͐ ͔ ͐ ͓ ͐ ͓ ͐ ͏ ͐ ͏ ͗ ͗ ͕ ͕ ͔ ͔ ͓ ͓ ͓ ͓ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͒ ͐ ͐ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͐ ͐ ͑ ͑ ͒ ͒ ͓ ͓ ͔ ͔ ͕ ͕ ͖ ͖ ͗ ͗ ͘ ͘ ͐ ͏ ͐ ͏ ͐ ͐ ͐ ͐ ͐ ͑ ͐ ͑ ͐ ͒ ͐ ͒ ͐ ͓ ͐ ͓ ͐ ͔ ͐ ͔ ͐ ͕ ͐ ͕ ͐ ͖ ͐ ͖ ͐ ͗ ͐ ͗ ͐ ͘ ͐ ͘ ͑ ͏ ͑ ͏ ͑ ͐ ͑ ͐ ͑ ͑ ͑ ͑ ͑ ͒ ͑ ͒ ͑ ͓ ͑ ͓ ͑ ͔ ͑ ͔ ͑ ͕ ͑ ͕ ͑ ͖ ͑ ͖ ͑ ͗ ͑ ͗ ͑ ͘ ͑ ͘ ͒ ͏ ͒ ͏ ͒ ͐ ͒ ͐ ͒ ͑ ͒ ͑ ͒ ͒ ͒ ͒ ͒ ͓ ͒ ͓ ͒ ͔ ͒ ͔ ͒ ͕ ͒ ͕ ͒ ͖ ͒ ͖ ͒ ͗ ͒ ͗ ͒ ͘ ͒ ͘ ͓ ͏ ͓ ͏ ͓ ͐ ͓ ͐ ͓ ͑ ͓ ͑ ͓ ͒ ͓ ͒ ͓ ͓ ͓ ͓ ͓ ͔ ͓ ͔ ͓ ͕ ͓ ͕ ͓ ͖ ͓ ͖ Lonca - R : R - GemOx : Censored : < 75 years old Median OS, months (95% CI): Lonca - R : 13.47 (10.78, 23.03) R - GemOx : 10.97 (8.21, 14.26) Hazard Ratio (95% CI) : 0.72 (0.52, 1.01) ≥ 75 years old ͏ ͏ ͐ ͐ ͑ ͑ ͒ ͒ ͓ ͓ ͔ ͔ ͕ ͕ ͖ ͖ ͗ ͗ ͘ ͘ ͐ ͏ ͐ ͏ ͐ ͐ ͐ ͐ ͐ ͑ ͐ ͑ ͐ ͒ ͐ ͒ ͐ ͓ ͐ ͓ ͐ ͔ ͐ ͔ ͐ ͕ ͐ ͕ ͐ ͖ ͐ ͖ ͐ ͗ ͐ ͗ ͐ ͘ ͐ ͘ ͑ ͏ ͑ ͏ ͑ ͐ ͑ ͐ ͑ ͑ ͑ ͑ ͑ ͒ ͑ ͒ ͑ ͓ ͑ ͓ ͑ ͔ ͑ ͔ ͑ ͕ ͑ ͕ ͑ ͖ ͑ ͖ ͑ ͘ ͑ ͘ ͒ ͒ ͏ ͏ ͒ ͐ ͒ ͐ ͒ ͑ ͒ ͑ ͒ ͒ ͒ ͒ ͒ ͓ ͒ ͓ ͒ ͔ ͒ ͔ ͒ ͕ ͒ ͕ ͒ ͖ ͒ ͖ ͒ ͗ ͒ ͗ ͒ ͘ ͒ ͘ ͓ ͏ ͓ ͏ ͓ ͐ ͓ ͐ ͓ ͑ ͓ ͑ ͓ ͒ ͓ ͒ ͓ ͓ ͓ ͓ ͓ ͔ ͓ ͔ ͓ ͕ ͓ ͕ ͑ ͗ ͏ ϟ ͏ ͏ ϟ ͐ ͏ ϟ ͑ ͏ ϟ ͒ ͏ ϟ ͓ ͏ ϟ ͔ ͏ ϟ ͕ ͏ ϟ ͖ ͏ ϟ ͗ ͏ ϟ ͘ ͐ ϟ ͏ „ Ř ĺ æ Í æ Ė ī Ė ťƅ ť ϙ Ř Ė Ŝ ħ ϙϡ [ ib ϱ ‡ ‡ ϱ @( a i³ ͗ ͖ ͗ ͖ ͗ ͖ ͗ ͖ ͗ ͓ ͗ ͓ ͗ ͐ ͗ ͐ ͖ ͐ ͖ ͐ ͕ ͖ ͕ ͖ ͔ ͘ ͔ ͘ ͔ ͑ ͔ ͑ ͓ ͗ ͓ ͗ ͓ ͓ ͓ ͓ ͓ ͏ ͓ ͏ ͒ ͗ ͒ ͗ ͒ ͓ ͒ ͓ ͑ ͘ ͑ ͘ ͑ ͗ ͑ ͗ ͑ ͖ ͑ ͖ ͑ ͓ ͑ ͓ ͑ ͓ ͑ ͓ ͑ ͒ ͑ ͒ ͑ ͑ ͑ ͑ ͐ ͗ ͐ ͗ ͐ ͕ ͐ ͕ ͐ ͔ ͐ ͔ ͐ ͓ ͐ ͓ ͐ ͑ ͐ ͑ ͐ ͐ ͐ ͐ ͘ ͘ ͘ ͘ ͗ ͗ ͖ ͖ ͖ ͖ ͔ ͔ ͓ ͓ ͒ ͒ ͒ ͒ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͖ ͘ ͖ ͘ ͖ ͔ ͖ ͔ ͕ ͘ ͕ ͘ ͕ ͑ ͕ ͑ ͔ ͘ ͔ ͘ ͔ ͓ ͔ ͓ ͓ ͗ ͓ ͗ ͓ ͗ ͓ ͗ ͓ ͖ ͓ ͖ ͓ ͓ ͓ ͓ ͓ ͑ ͓ ͑ ͓ ͏ ͓ ͏ ͒ ͘ ͒ ͘ ͒ ͕ ͒ ͕ ͒ ͒ ͒ ͒ ͒ ͏ ͒ ͏ ͑ ͘ ͑ ͘ ͑ ͔ ͑ ͔ ͑ ͔ ͑ ͔ ͑ ͓ ͑ ͓ ͑ ͑ ͑ ͑ ͑ ͑ ͑ ͑ ͐ ͘ ͐ ͘ ͐ ͗ ͐ ͗ ͐ ͕ ͐ ͕ ͐ ͔ ͐ ͔ ͐ ͔ ͐ ͔ ͐ ͒ ͐ ͒ ͐ ͒ ͐ ͒ ͐ ͒ ͐ ͒ ͐ ͐ ͐ ͐ ͐ ͏ ͐ ͏ ͐ ͏ ͐ ͏ ͘ ͘ ͘ ͘ ͘ ͘ ͗ ͗ ͕ ͕ ͔ ͔ ͓ ͓ ͒ ͒ ͒ ͒ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͐ ͏ ͏ “ Ė ı ôϙ ϼ ı ĺ IJ ť ē Ŝ Ͻ Median OS, months (95% CI): Lonca - R : 9.86 (7.16, 12.29) R - GemOx : 13.90 (8.97, NE) Hazard Ratio (95% CI) : 1.38 (0.93, 2.06) Patients at risk: Patients at risk:
Treatment Emergent Adverse Events Leading to Any Study Drug Withdrawal LOTIS - 5 Topline Results 28 >2% in Either Treatment Arm by Group Term or Preferred Term *Group Term is based on either System Organ Class (SOC) or AEs of Special Interest (AESI) category TEAE reporting window defined as 105 days after the last dose of study treatment or start of new anticancer therapy, whicheve r i s earlier. Treated population, N=401; Data cut off: February 16, 2026. R - GemOx (N=197) n (%) Lonca - R (N=204) n (%) Grouped Term* / Preferred Term 18 (9.1%) 52 (25.5%) Patients with TEAE leading to any study drug withdrawal 4 (2.0%) 14 (6.9%) Infections and infestations (SOC) 0 9 (4.4%) Pneumonia 2 (1.0%) 10 (4.9%) Oedema and Effusions (AESI) 2 (1.0%) 9 (4.4%) Pleural Effusions 0 4 (2.0%) Pericardial Effusions 0 7 (3.4%) Hepatoxicity (AESI) 0 4 (2.0%) Gamma - glutamyltransferase increased 5 (2.5%) 5 (2.5%) Blood and lymphatic system disorders (SOC) 3 (1.5%) 5 (2.5%) Thrombocytopenia
LOTIS - 5 Topline Results 29 >2% in Either Treatment Arm by Group Term or Preferred Term Serious Treatment Emergent Adverse Events *Group Term is based on either System Organ Class (SOC) or AEs of Special Interest (AESI) category Serious Adverse Event (SAE): An AE resulting in death, life - threatening condition, hospitalization or its prolongation, persiste nt or significant disability, congenital anomaly/birth defect, or a medically significant event that may jeopardize the patient or require intervention to prevent the se outcomes. TEAE reporting window defined as 105 days after the last dose of study treatment or start of new anticancer therapy, whicheve r i s earlier. Treated population, N=401; Data cut off: February 16, 2026. R - GemOx (N=197) n (%) Lonca - R (N=204) n (%) Group Term* / Preferred Term 68 (34.5 % ) 100 (49.0%) Patients with any serious TEAE 29 (14.7%) 48 (23.5%) Infections and infestations (SOC) 11 (5.6 % ) 26 (12.7 % ) Pneumonia 1 (0.5 % ) 7 (3.4 % ) COVID - 19 1(0.5%) 20 (9.8%) Oedema and Effusions (AESI) 1(0.5 % ) 16 (7.8 % ) Pleural Effusions 19 (9.6%) 15 (7.4%) Blood and lymphatic system disorders (SOC) 4 (2.0 % ) 5 (2.5 % ) Febrile neutropenia 9 (4.6 % ) 4 (2.0 % ) Thrombocytopenia